|
12:00–12:20
|
Distinct Clinical features of NMO: Importance of a timely & accurate
Friedemann Paul (Berlin/DE) Redezeit: 20 min |
|
||
|
12:20–12:40
|
Targeting and maximizing B-cell depletion – Should a B-cell depleter be used after a B-cell deplete failure?
Martin Weber (Göttingen/DE) Redezeit: 20 min |
|
||
|
12:40–13:00
|
New therapeutic options in NMOSD
Ingo Kleiter (Berg/DE) Redezeit: 20 min |
|
||
|
13:00–13:20
|
Defining treatment failure, what to do next?
Orhan Aktas (Düsseldorf/DE) Redezeit: 20 min |
|
||
|
13:20–13:30
|
Q&A
Hans-Peter Hartung (Düsseldorf/DE) |
|
||